Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5–80 years in India: a phase 3, single-blind, randomised controlled trial

Authors

SubbaReddy Gunneri
Subhash Thuluva (ORCID: https://orcid.org/0000-0002-9099-420X)
Aparna Rao (ORCID: https://orcid.org/0000-0001-8120-8740)
Rammohan Reddy Mogulla (ORCID: https://orcid.org/0000-0001-6638-7701)
Chirag Dhar (ORCID: https://orcid.org/0000-0002-7351-485X)
Vikram Paradkar (ORCID: https://orcid.org/0000-0001-9500-7237)
Manish Narang (ORCID: https://orcid.org/0000-0002-6889-0797)
Vijay Yerroju (ORCID: https://orcid.org/0000-0003-4192-3760)
Mallikarjuna Panchakshari (ORCID: https://orcid.org/0000-0002-2060-1220)
Shivnitwar Sachin Kisan
Chandrashekhar S. Gillurkar
Siddalingaiah Ningaiah (ORCID: https://orcid.org/0009-0006-6116-4959)

Institutions

Guru Teg Bahadur Hospital (IN)
Midas Multispeciality Hospital (IN)
Axis Multispecialty Hospital (IN)
Biological E (India) (IN)
St. Theresa’s Multi-Speciality Hospital (IN)

Publication Details

Journal: The Lancet Regional Health - Southeast Asia
Published: 2025-07-24
DOI: https://doi.org/10.1016/j.lansea.2025.100642
Citations: 4
Primary Topic: SARS-CoV-2 and COVID-19 Research
Type: article
Field-Weighted Citation Impact: 5.58

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5–80 years in India: a phase 3, single-blind, randomised controlled trial

SubbaReddy Gunneri, Subhash Thuluva, Aparna Rao, Rammohan Reddy Mogulla et al.

Jul 24, 2025

4 citations

The Lancet Regional Health - Southeast Asia

SARS-CoV-2 and COVID-19 Research

5.58

article

Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5–80 years in India: a phase 3, single-blind, randomised controlled trial

SubbaReddy Gunneri, Subhash Thuluva, Aparna Rao, Rammohan Reddy Mogulla, Chirag Dhar, Vikram Paradkar, Manish Narang, Vijay Yerroju, Mallikarjuna Panchakshari, Shivnitwar Sachin Kisan, Chandrashekhar S. Gillurkar, Siddalingaiah Ningaiah

July 24, 2025article en

4 citations

Abstract

No abstract available for this paper.

The Lancet Regional Health - Southeast AsiaVol. 40

Guru Teg Bahadur Hospital (IN), Midas Multispeciality Hospital (IN), Axis Multispecialty Hospital (IN), Biological E (India) (IN), St. Theresa’s Multi-Speciality Hospital (IN)

Good health and well-being

Openalex Percentile: Top 4%

SARS-CoV-2 and COVID-19 Research

5.58

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5–80 years in India: a phase 3, single-blind, randomised controlled trial — SubbaReddy Gunneri, Subhash Thuluva, et al. · The Lancet Regional Health - Southeast Asia (2025) | TGRS Research Map | TGRS